Single center prospective phase II trial of CT-guided radiofrequency ablation for pulmonary metastases from colorectal cancer (SCIRO-1401)

Jun Sakurai; Yusuke Matsui; Takao Hiraki; Toshihiro Iguchi; Hiroyasu Fujiwara; Hideo Gobara; Toshiharu Mitsuhashi; Takeshi Nagasaka; Susumu Kanazawa

Single center prospective phase II trial of CT-guided radiofrequency ablation for pulmonary metastases from colorectal cancer (SCIRO-1401)

Jun Sakurai, Yusuke Matsui, Takao Hiraki, Toshihiro Iguchi, Hiroyasu Fujiwara, Hideo Gobara, Toshiharu Mitsuhashi, Takeshi Nagasaka, Susumu Kanazawa

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

The present single center prospective phase II clinical trial is designed to evaluate the efficacy and safety of percutaneous radiofrequency (RF) ablation for colorectal lung metastases. Patients who have colorectal lung metastases without extrapulmonary metastases are included in this study. The primary endpoint is 3-year overall survival (OS) after RF ablation. The secondary endpoints are the prevalence of adverse events within 4 weeks, local tumor progression rate, 1- and 5-year OS, cause-specific survival, and relapse-free survival. The recruitment of patients commenced in July 2014, and the enrolment of 45 patients is intended over the 3 years of study period.

Original language	English
Pages (from-to)	317-322
Number of pages	6
Journal	Acta medica Okayama
Volume	70
Issue number	4
Publication status	Published - 2016

Keywords

Colorectal cancer
Lung metastasis
Radiofrequency ablation

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{cdaad866a29e4f94832fd2942856c526,

title = "Single center prospective phase II trial of CT-guided radiofrequency ablation for pulmonary metastases from colorectal cancer (SCIRO-1401)",

abstract = "The present single center prospective phase II clinical trial is designed to evaluate the efficacy and safety of percutaneous radiofrequency (RF) ablation for colorectal lung metastases. Patients who have colorectal lung metastases without extrapulmonary metastases are included in this study. The primary endpoint is 3-year overall survival (OS) after RF ablation. The secondary endpoints are the prevalence of adverse events within 4 weeks, local tumor progression rate, 1- and 5-year OS, cause-specific survival, and relapse-free survival. The recruitment of patients commenced in July 2014, and the enrolment of 45 patients is intended over the 3 years of study period.",

keywords = "Colorectal cancer, Lung metastasis, Radiofrequency ablation",

author = "Jun Sakurai and Yusuke Matsui and Takao Hiraki and Toshihiro Iguchi and Hiroyasu Fujiwara and Hideo Gobara and Toshiharu Mitsuhashi and Takeshi Nagasaka and Susumu Kanazawa",

year = "2016",

language = "English",

volume = "70",

pages = "317--322",

journal = "Acta medica Okayama",

issn = "0386-300X",

publisher = "Okayama University",

number = "4",

}

TY - JOUR

T1 - Single center prospective phase II trial of CT-guided radiofrequency ablation for pulmonary metastases from colorectal cancer (SCIRO-1401)

AU - Sakurai, Jun

AU - Matsui, Yusuke

AU - Hiraki, Takao

AU - Iguchi, Toshihiro

AU - Fujiwara, Hiroyasu

AU - Gobara, Hideo

AU - Mitsuhashi, Toshiharu

AU - Nagasaka, Takeshi

AU - Kanazawa, Susumu

PY - 2016

Y1 - 2016

N2 - The present single center prospective phase II clinical trial is designed to evaluate the efficacy and safety of percutaneous radiofrequency (RF) ablation for colorectal lung metastases. Patients who have colorectal lung metastases without extrapulmonary metastases are included in this study. The primary endpoint is 3-year overall survival (OS) after RF ablation. The secondary endpoints are the prevalence of adverse events within 4 weeks, local tumor progression rate, 1- and 5-year OS, cause-specific survival, and relapse-free survival. The recruitment of patients commenced in July 2014, and the enrolment of 45 patients is intended over the 3 years of study period.

AB - The present single center prospective phase II clinical trial is designed to evaluate the efficacy and safety of percutaneous radiofrequency (RF) ablation for colorectal lung metastases. Patients who have colorectal lung metastases without extrapulmonary metastases are included in this study. The primary endpoint is 3-year overall survival (OS) after RF ablation. The secondary endpoints are the prevalence of adverse events within 4 weeks, local tumor progression rate, 1- and 5-year OS, cause-specific survival, and relapse-free survival. The recruitment of patients commenced in July 2014, and the enrolment of 45 patients is intended over the 3 years of study period.

KW - Colorectal cancer

KW - Lung metastasis

KW - Radiofrequency ablation

UR - http://www.scopus.com/inward/record.url?scp=84984861452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984861452&partnerID=8YFLogxK

M3 - Article

C2 - 27549681

AN - SCOPUS:84984861452

SN - 0386-300X

VL - 70

SP - 317

EP - 322

JO - Acta medica Okayama

JF - Acta medica Okayama

IS - 4

ER -

Single center prospective phase II trial of CT-guided radiofrequency ablation for pulmonary metastases from colorectal cancer (SCIRO-1401)

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this